InvestorsHub Logo
Followers 466
Posts 26938
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 108

Friday, 02/03/2012 9:16:51 AM

Friday, February 03, 2012 9:16:51 AM

Post# of 539
7:00AM Acorda Therapeutics presents preclinical data showing Dalfampridine improves motor function in chronic stroke (ACOR) 26.30 : Co presented data showing that treatment with dalfampridine improved motor function in a preclinical model of stroke, with treatment initiated at least four weeks following the ischemic event. Co plans to begin a proof-of-concept trial of AMPYRA in stroke by the end of 2012. Dalfampridine, also known as 4-aminopyridine, is the active chemical ingredient in AMPYRA Extended Release Tablets, 10 mg. AMPYRA is approved in the United States as a treatment to improve walking in patients with multiple sclerosis.


surf's up......crikey



Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.